The better the efficacy of a systemic treatment, the higher the patient satisfaction, especially if the risk-benefit balance is favorable. This plausible correlation is impressively underpinned by current findings from psoriasis research. In view of the wide range of treatments available, it is becoming increasingly important to select therapies that are tailored to individual patient characteristics. Analyses of the PsoBest registry and data sets from the “Adelphi Real World PsO Disease Specific Program” as well as other registry studies and survey data provide valuable insights in this regard.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Innovative Oral Treatment Options for Psoriasis: Icotrokinra and Zasocitinib
First-class immunomodulation combined with convenience—the data available so far is convincing
- Preclinical Study on a Special Ginkgo biloba Extract
What role do proanthocyanidins play?
- Myasthenia gravis: immunomodulatory therapies for long-term treatment
Expanded Possibilities Thanks to Innovative Classes of Active Ingredients
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Interstitial Lung Diseases
Update on Idiopathic Pulmonary Fibrosis
- Ischemic stroke: Are smaller or larger brain arteries affected?
Recent study findings on intravenous lysis therapy with fibrinolytic agents
- Interview
“On par with the gold standards for trauma”
- Psychology: Emotional Freedom Techniques (EFT)